Document:

Amendment to Deferred Compensation Agreement - Warren P. Levy

 Exhibit 10.19 
 December 19, 2008 
 Dr. Warren P. Levy 
 President & Chief Executive Officer 
 Unigene Laboratories, Inc.

 81 Fulton Street 
 Boonton, NJ 07005 
 Re:    Amendment to Nonqualified Deferred Compensation Agreement 
 Dear Warren, 
 Reference is made to the Nonqualified Deferred Compensation Agreement (the “Deferred
Compensation Agreement”) dated February 1, 2006, by and between you and Unigene Laboratories, Inc. (the “Company”). 
 By
signing this letter agreement, you and the Company, intending to be legally bound, hereby amend the Deferred Compensation Agreement as follows, effective December 31, 2008: 
 The paragraph of the Deferred Compensation Agreement entitled “Acceleration of Annual Credits” is hereby amended and restated in its
entirety, to read as follows: 
 “Acceleration of Annual Credits. Notwithstanding anything herein to the contrary, in the event of
your death, disability, or in the event that there occurs a “change in the ownership or effective control” of the Company or a “change in the ownership of a substantial portion of the assets” of the Company, each within the
meaning ascribed to such events by Section 409A of the Internal Revenue Code and the applicable guidance issued thereunder (any such event, a “Change in Control”), all remaining Annual Credits will be accelerated and immediately
credited to your Account.” 
 In addition, the paragraph of the Deferred Compensation Agreement entitled
“Distributions” is hereby amended to add the following sentence to the end thereof: 
 “Notwithstanding anything to the
contrary herein, each distribution to which you are entitled under this Agreement as a result of your death or disability shall be paid to you (or to your estate, if applicable) as soon as practicable, but in no event later than 90 days following
such death or disability, or the first anniversary thereof, as applicable.” 
 [Signature page follows] 

 Except as amended hereby, the Deferred Compensation Agreement is affirmed and ratified in all respects.

  

			
	Sincerely,
	
	UNIGENE LABORATORIES, INC.
		
	By:	 	 /s/ Robert F. Hendrickson

		 	 Robert F. Hendrickson, Chair of the Compensation Committee
 For the Board of Directors

 ACCEPTED AND AGREED this 19th day of December, 2008: 
  

			
	 /s/ Dr. Warren P. Levy

	Dr. Warren P. LevyAmendment to Deferred Compensation Agreement - Ronald S. Levy

 Exhibit 10.20 
 December 22, 2008 
 Dr. Ronald S. Levy 
 Executive Vice President 
 Unigene Laboratories, Inc. 
 81 Fulton Street 
 Boonton, NJ 07005 
 Re:    Amendment to Nonqualified Deferred Compensation Agreement 
 Dear Ron, 
 Reference is made to the Nonqualified Deferred Compensation Agreement (the “Deferred
Compensation Agreement”) dated February 1, 2006, by and between you and Unigene Laboratories, Inc. (the “Company”). 
 By
signing this letter agreement, you and the Company, intending to be legally bound, hereby amend the Deferred Compensation Agreement as follows, effective December 31, 2008: 
 The paragraph of the Deferred Compensation Agreement entitled “Acceleration of Annual Credits” is hereby amended and restated in its
entirety, to read as follows: 
 “Acceleration of Annual Credits. Notwithstanding anything herein to the contrary, in the event of
your death, disability, or in the event that there occurs a “change in the ownership or effective control” of the Company or a “change in the ownership of a substantial portion of the assets” of the Company, each within the
meaning ascribed to such events by Section 409A of the Internal Revenue Code and the applicable guidance issued thereunder (any such event, a “Change in Control”), all remaining Annual Credits will be accelerated and immediately
credited to your Account.” 
 In addition, the paragraph of the Deferred Compensation Agreement entitled
“Distributions” is hereby amended to add the following sentence to the end thereof: 
 “Notwithstanding anything to the
contrary herein, each distribution to which you are entitled under this Agreement as a result of your death or disability shall be paid to you (or to your estate, if applicable) as soon as practicable, but in no event later than 90 days following
such death or disability, or the first anniversary thereof, as applicable.” 
 [Signature page follows] 

 Except as amended hereby, the Deferred Compensation Agreement is affirmed and ratified in all respects.

  

			
	Sincerely,
	
	UNIGENE LABORATORIES, INC.
		
	By	 	 /s/ Robert F. Hendrickson

		 	 Robert F. Hendrickson, Chair of the Compensation Committee
 For the Board of Directors

 ACCEPTED AND AGREED this 22nd day of December, 2008: 
  

			
	 /s/ Dr. Ronald S. Levy

	Dr. Ronald S. LevyGuarantee

 Exhibit 10.1 
 EXECUTION COPY 
 GUARANTEE 
 GUARANTEE dated as of March 12, 2009 by Roche Holding Ltd, a joint stock company organized under the laws of Switzerland (the
“Guarantor”), for the benefit of Genentech, Inc. (together with its successors and permitted assigns, the “Beneficiary”). 
 W I T N E S S E T H : 
 WHEREAS, Roche Holdings, Inc., a Delaware corporation (together with its
successors and assigns under the Merger Agreement, the “Obligor”) is an indirect wholly-owned subsidiary of the Guarantor; and 
 WHEREAS, the Obligor has entered into an Agreement and Plan of Merger dated as of March 12, 2009 (as amended, modified or supplemented from time to time, the “Merger Agreement”) among the Beneficiary, the Obligor and
Roche Investments USA Inc. (the “Merger Subsidiary”); and 
 WHEREAS, this Guarantee is being made at the request of the
Obligor and the Beneficiary; 
 NOW, THEREFORE, in consideration of the promises and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Guarantor agrees as follows: 
 1. The Guarantee, etc. The Guarantor hereby
unconditionally and irrevocably guarantees the full and punctual performance and discharge of the Obligor’s and Merger Subsidiary’s (and their permitted assigns’) payment and performance obligations, including the obligation to cause
the Merger Subsidiary to perform its obligations, under the Merger Agreement (each a “Guaranteed Obligation”). The Guaranteed Obligations include, without limitation, an unconditional guarantee of payment and performance and not of
collectability. 
 2. Guarantee Unconditional. The obligations of the Guarantor hereunder shall be unconditional and absolute and,
without limiting the generality of the foregoing, shall not be released, discharged or otherwise affected by: 
 (a) any
extension, other indulgence, renewal, settlement, compromise, discharge (other than payment in full or full performance of obligations), waiver, subordination or release in respect of any obligation of the Obligor or Merger Subsidiary under the
Merger Agreement, by operation of law or otherwise; 
 (b) any modification or amendment of or supplement to the Merger
Agreement; 

 (c) any change in the corporate existence, structure or ownership of the Obligor or
Merger Subsidiary, or any insolvency, bankruptcy, reorganization or other similar proceeding affecting the Obligor or Merger Subsidiary or their respective assets or any resulting release or discharge of any obligation of the Obligor or Merger
Subsidiary contained in the Merger Agreement; 
 (d) the existence of any claim, set-off, counterclaim or other rights which
the Guarantor may have at any time against the Obligor or Merger Subsidiary, the Beneficiary or any other Person; provided that nothing herein shall prevent the assertion of any such claim by separate suit or compulsory counterclaim;

 (e) any incapacity or lack of power, authority or legal personality, or change in the existence, structure, constitution,
name, control or ownership of the Obligor or Merger Subsidiary; 
 (f) any defense arising by reason of any failure of
Beneficiary to proceed against Obligor or any other person, or to apply or exhaust any security held from Obligor or any other person for all or any part of the Obligations, to proceed against, apply or exhaust any security held from the Guarantor
or any other person, or to pursue any other remedy available to the Beneficiary or to realize full value of any security and any defense relating to any impairment of Guarantor’s right of subrogation; 
 (g) any defense arising by reason of breach by Obligor or the Merger Subsidiary of any representation, warranty or covenant contained in
the Merger Agreement; or 
 (h) any other event, act or omission to act or delay of any kind by the Obligor or the Merger
Subsidiary, the Beneficiary or any other Person or any other circumstance whatsoever which might, but for the provisions of this paragraph, constitute a legal or equitable discharge of or defense to the Guarantor’s obligations hereunder.

 3. Discharge Only Upon Satisfaction in Full. The Guarantor’s obligations hereunder shall remain in full force and effect until
all Guaranteed Obligations shall have been irrevocably paid or performed in full. In the event that any payment to the Beneficiary in respect of any Guaranteed Obligation is rescinded or must otherwise be returned for any reason whatsoever
(including, without limitation, the insolvency, bankruptcy or reorganization of the Obligor or the Merger Subsidiary), the Guarantor shall remain liable hereunder with respect to such Guaranteed Obligation as if such payment had not been made. The
Guarantor hereby unconditionally and irrevocably agrees not to exercise any rights that it may now have or hereafter acquire against the Obligor or any other Person primarily or secondarily liable with respect to any of the Guaranteed Obligations
that arise from the existence, payment, performance or enforcement 

  

 2 

 
of the Guarantor’s obligations hereunder including, without limitation, any right of subrogation, reimbursement, exoneration, contribution or
indemnification and any right to participate in any claim or remedy of the Beneficiary against any other Person primarily or secondarily liable with respect to any of the Guaranteed Obligations, whether such claim, remedy or right arises in equity
or under contract, statute or common law, including, without limitation, the right to take or receive from the Obligor or any other Person primarily or secondarily liable with respect to any of the Guaranteed Obligations, directly or indirectly, in
cash or other property or by set-off or in any other manner, payment or security on account of such claim, remedy or right, in each case unless and until all of the Guaranteed Obligations and all other amounts payable under this Guarantee shall have
been paid in full in cash. If any amount shall be paid to the Guarantor in violation of the immediately preceding sentence, such amount shall be received and held in trust for the benefit of the Beneficiary, and shall forthwith be paid or delivered
to the Beneficiary in the same form as so received (with any necessary endorsement or assignment) to be credited and applied to the amounts payable under this Guarantee. 
 4. Additional Waivers by the Guarantor. Provided that the Beneficiary shall have made a request (oral or written) to the Obligor for payment or performance (which procedural requirement to make such a request
shall not apply in the event of the initiation of pendency of any proceedings with respect to the Obligor or Guarantor under any applicable bankruptcy, liquidation, insolvency, reorganization or similar laws), the Guarantor irrevocably waives
acceptance hereof, presentment, demand, protest and any notice not provided for herein, as well as any requirement that at any time any action be taken by any Person against the Obligor, the Guarantor or any other Person. The Beneficiary need not
exhaust any recourse that it may have against the Obligor or other persons before being entitled to full payment and performance from the Guarantor under this Guarantee. 
 5. Representations and Warranties. The Guarantor represents and warrants to the Beneficiary that: 
 (a) the Guarantor is duly organized and validly existing under the laws of the jurisdiction of its organization; 
 (b) the execution, delivery and performance by the Guarantor of this Guarantee are within the Guarantor’s corporate powers and have been duly authorized by all necessary corporate action; 
 (c) this Guarantee has been duly executed and delivered by the Guarantor and constitutes a valid and binding obligation of the Guarantor;

 (d) the execution, delivery and performance of this Guarantee (i) do not require any consent or approval of,
registration or filing with, or other action by, any governmental authority, except such as have been obtained 

  

 3 

 
and are in full force and effect, (ii) will not violate any applicable law or regulation or the charter, by-laws or other organizational documents of
the Guarantor or any order of any court or governmental authority by which the Guarantor is bound, and (iii) will not violate or result in a default under any indenture, agreement or other instrument binding upon the Guarantor or any of its
properties or give rise to a right thereunder to require the Guarantor to make any payment; 
 (e) it is not necessary that
any stamp, registration or similar tax be paid in order to render this Guarantee enforceable against the Guarantor; and 
 (f)
it is not, as at the date of this Guarantee, required to make any deduction for or on account of any Tax from any payment it may make under this Guarantee and agrees that if any such Tax is due it will promptly pay to Beneficiary such additional
amount or amounts as may be necessary to compensate Beneficiary for any such Tax. 
 6. Notices. All notices, requests and other
communications to any party hereunder shall be in writing (including facsimile transmission and electronic mail transmission, so long as a receipt of such e-mail is requested and received) and shall be given, as follows: 
 (i) if to the Guarantor, to it at: 
 Roche
Holding Ltd 
 Grenzacherstrasse 124 
 CH-4070 Basel 
 Switzerland 
 Attention: Corporate Legal Department 
 Facsimile No.: +41 61 688 9541 

			
	e-mail:	  	gottlieb.keller@roche.com
		  	beat.kraehenmann@roche.com

 with copies to: 
 Roche Holdings, Inc. 
 1220 N. Market St., Suite #334 
 Wilmington, Delaware 19801-2535 
 Attention:
Carol Fiederlein 
 Facsimile No.: (302) 425-4713 

			
	e-mail:	  	carol.fiederlein.cf1@roche.com

 and 
  

 4 

 Davis Polk & Wardwell 
 450 Lexington Avenue 
 New York, New York
10017 

			
	Attention:	 	 Arthur F. Golden
 Christopher
Mayer

			
	Facsimile No.:	 	(212) 450-3388
		 	(212) 450-3338

			
	e-mail:	 	 arthur.golden@dpw.com
 chris.mayer@dpw.com

 (ii) if to the Beneficiary, to it at: 
 Special Committee of the Board of Directors 
 c/o Genentech, Inc. 
 1 DNA Way 
 South San Francisco, California 94080-4990 
 Attention: Chairman of the Special Committee of the Board of
Directors 
 Facsimile No.: (919) 932-7588 
 e-mail: csanders@gene.com 
 with copies to: 
 Latham & Watkins LLP 
 140 Scott
Drive 
 Menlo Park CA 94025 
 Attention: Peter F. Kerman 
 Facsimile No.: (650) 463-2600 
 e-mail: peter.kerman@lw.com 
 and 

Genentech, Inc. 
 1 DNA Way 
 South San Francisco, California 94080-4990 
 Attention: Sean A. Johnston 
 Facsimile No.: (650) 952-9881 
 e-mail: johnston.sean@gene.com 
 and 
  

 5 

 Wilson Sonsini Goodrich & Rosati 
 650 Page Mill Road 
 Palo Alto, CA 94304

			
	Attention:	 	 Larry W. Sonsini
 Martin W.
Korman

	Facsimile No.: (650) 493-6811
	e-mail:	 	 lsonsini@wsgr.com
 mkorman@wsgr.com

 or to such other address or facsimile number as such party may hereafter specify for the purpose by notice to the
other parties hereto. All such notices, requests and other communications shall be deemed received on the date of receipt by the recipient thereof if received prior to 5 p.m. on a business day in the place of receipt. Otherwise, any such notice,
request or communication shall be deemed to have been received on the next succeeding business day in the place of receipt. 
 7. Defined
Terms. Capitalized terms used but not defined herein shall have the meanings assigned to them in the Merger Agreement. 
 8. No
Waiver. No failure or delay by the Beneficiary in exercising any right, power or privilege under this Guarantee or the Merger Agreement shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or
further exercise thereof or the exercise of any other right, power or privilege. 
 9. Amendments and Waivers. Any provision of this
Guarantee may be amended or waived if, but only if, such amendment or waiver is in writing and is signed by the Beneficiary and the Guarantor. 
 10. Successors and Assigns. This Guarantee shall be binding upon the Guarantor and its successors and permitted assigns, for the benefit of the Beneficiary and its successors and assigns. Neither the Beneficiary nor the Guarantor may
assign its rights, duties or obligations hereunder to any other Person (except by operation of law) without the prior written consent of the other party. 
 11. Governing Law. This Guarantee shall be governed by and construed in accordance with the law of the State of Delaware, without regard to the conflicts of law rules of such state. 
 12. Jurisdiction. The parties hereto agree that any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising
out of or in connection with or relating to, this Guarantee or the transactions contemplated hereby shall be brought in the Court of Chancery of the State of Delaware in and for New Castle County, Delaware, and each of the parties hereby irrevocably
consents to the exclusive jurisdiction of such court (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and 

  

 6 

 
irrevocably waives, to the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of the venue of any such suit,
action or proceeding in any such court or that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. Process in any such suit, action or proceeding against any party may be served anywhere in the
world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each party agrees that service of process as provided in Section 6 shall be deemed effective service of process on such party. 
 13. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR
RELATED TO THIS GUARANTEE OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 14. Expenses. The Guarantor agrees to pay all out-of-pocket
expenses (including, without limitation, the reasonable fees and expenses of the Beneficiary’s counsel) incurred by the Beneficiary in connection with the successful enforcement of the rights of the Beneficiary hereunder. 
 * * * * * 
  

 7 

			
	ROCHE HOLDING LTD
		
	By:	 	 /s/ Dr. Beat Kraehenmann

	Name:	 	Dr. Beat Kraehenmann
	Title:	 	Authorized Signatory
		
	By:	 	 /s/ Steve Krognes

	Name:	 	Steve Krognes
	Title:	 	Authorized Signatory

  

			
	Agreed to and accepted by:
	
	GENENTECH, INC.
		
	By:	 	 /s/ Arthur D. Levinson

	Name:	 	Arthur D. Levinson
	Title:	 	Chairman and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]